Connection

CHRISTINE BEETON to Kv1.3 Potassium Channel

This is a "connection" page, showing publications CHRISTINE BEETON has written about Kv1.3 Potassium Channel.
Connection Strength

4.381
  1. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog. Clin Immunol. 2017 07; 180:45-57.
    View in: PubMed
    Score: 0.574
  2. Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK. Mar Drugs. 2015 Jan 16; 13(1):529-42.
    View in: PubMed
    Score: 0.493
  3. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol Chem. 2014 May 02; 289(18):12623-32.
    View in: PubMed
    Score: 0.465
  4. The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation. J Biol Chem. 2008 Jan 11; 283(2):988-97.
    View in: PubMed
    Score: 0.299
  5. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17414-9.
    View in: PubMed
    Score: 0.279
  6. Potassium channels, memory T cells, and multiple sclerosis. Neuroscientist. 2005 Dec; 11(6):550-62.
    View in: PubMed
    Score: 0.262
  7. A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis. Proc Natl Acad Sci U S A. 2023 01 10; 120(2):e2211977120.
    View in: PubMed
    Score: 0.214
  8. KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis. Arthritis Res Ther. 2019 01 07; 21(1):6.
    View in: PubMed
    Score: 0.162
  9. Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats. Sci Rep. 2017 06 16; 7(1):3756.
    View in: PubMed
    Score: 0.146
  10. N-Terminally extended analogues of the K? channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3. FEBS J. 2015 Jun; 282(12):2247-59.
    View in: PubMed
    Score: 0.125
  11. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB J. 2014 Sep; 28(9):3952-64.
    View in: PubMed
    Score: 0.118
  12. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases. Sci Rep. 2014 Mar 28; 4:4509.
    View in: PubMed
    Score: 0.116
  13. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation. PLoS One. 2013; 8(11):e78712.
    View in: PubMed
    Score: 0.113
  14. Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One. 2013; 8(10):e76740.
    View in: PubMed
    Score: 0.113
  15. A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3. FEBS Lett. 2012 Nov 16; 586(22):3996-4001.
    View in: PubMed
    Score: 0.105
  16. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. J Pharmacol Exp Ther. 2012 Sep; 342(3):642-53.
    View in: PubMed
    Score: 0.103
  17. Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells. Mol Pharmacol. 2012 Sep; 82(3):372-82.
    View in: PubMed
    Score: 0.102
  18. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflamm Allergy Drug Targets. 2011 Oct; 10(5):313-21.
    View in: PubMed
    Score: 0.098
  19. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol. 2009 Apr; 75(4):762-73.
    View in: PubMed
    Score: 0.081
  20. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 2008 Oct 17; 29(4):602-14.
    View in: PubMed
    Score: 0.080
  21. Discovery on Target 2007--CHI's Fifth Annual Conference. Ion channels. IDrugs. 2007 Dec; 10(12):851-4.
    View in: PubMed
    Score: 0.075
  22. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol. 2005 Apr; 67(4):1369-81.
    View in: PubMed
    Score: 0.062
  23. Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins. J Biol Chem. 2004 Dec 31; 279(53):55690-6.
    View in: PubMed
    Score: 0.061
  24. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J Biol Chem. 2003 Mar 14; 278(11):9928-37.
    View in: PubMed
    Score: 0.053
  25. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A. 2005 Aug 02; 102(31):11094-9.
    View in: PubMed
    Score: 0.016
  26. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun; 65(6):1364-74.
    View in: PubMed
    Score: 0.015
  27. Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel. 2003 Sep; 6(5):640-7.
    View in: PubMed
    Score: 0.014
  28. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest. 2003 Jun; 111(11):1703-13.
    View in: PubMed
    Score: 0.014
  29. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A. 2001 Nov 20; 98(24):13942-7.
    View in: PubMed
    Score: 0.012
  30. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol. 2001 Jan 15; 166(2):936-44.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.